search
Back to results

Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin

Primary Purpose

Pain, Postoperative, Surgery, Thoracic

Status
Completed
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
Gabapentin
Placebo
Sponsored by
National Institute for Tuberculosis and Lung Diseases, Poland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Postoperative pain, Anxiety, Postoperative Complications, Patient Satisfaction

Eligibility Criteria

5 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 5 - 18 years of age;
  • surgery: lateral thoracotomy or Ravitch procedure;
  • ASA 1-3;
  • postoperative analgesia: thoracic epidural analgesia or intravenous infusion of morphine.

Exclusion Criteria:

  • allergy or sensitivity to gabapentin;
  • history of chronic pain or daily analgesic use;
  • diagnosed with psychiatric disorders;
  • treated oncologically;
  • with impaired verbal communication;
  • the lack of postoperative chest drainage.

Sites / Locations

  • Institute for Tuberculosis and Lung Diseases, Pediatric Division

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Gabapentin

Placebo Control

Arm Description

Single dose preoperative gabapentin. After surgery gabapentin 2 times per day for 3 days.

Single dose preoperative placebo control. After surgery placebo 2 times per day for 3 days.

Outcomes

Primary Outcome Measures

Pain intensity scores at rest (FLACC for patients <7 y.o., NRS for patients >7 y.o.)
Pain intensity scores during deep breathing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)
Pain intensity scores during coughing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)

Secondary Outcome Measures

Total ropivacaine/fentanyl consumption.
Total morphine consumption.
Anxiety intensity scores.
Patients rate their anxiety using State-Trait Anxiety Inventory.
Side Effect Occurrence
Incidence and severity of nausea, vomiting, pruritis, sedation, dizziness, urinary retention, complication in relation to administering of the drugs to epidural space.
The number of doses of metamizol as a "rescue drug"
Patient satisfaction.
Responses can range from 0 (very dissatisfied) to 10 (very satisfied).

Full Information

First Posted
December 28, 2017
Last Updated
August 31, 2021
Sponsor
National Institute for Tuberculosis and Lung Diseases, Poland
search

1. Study Identification

Unique Protocol Identification Number
NCT03393702
Brief Title
Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin
Official Title
Efficacy of Gabapentin as Adjuvant for Postoperative Pain in Pediatric Thoracic Surgery - a Randomized Quadruple Blind Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
May 9, 2017 (Actual)
Primary Completion Date
December 30, 2019 (Actual)
Study Completion Date
December 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute for Tuberculosis and Lung Diseases, Poland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study is performed in patients aged 5-18 years after thoracic surgery. The primary aim of this trial is to determine whether the use of gabapentin as a component of multimodal analgesic regiments reduces pain scores following thoracic surgery in pediatric patients. The secondary objective of the trial are to evaluate whether the use of gabapentin reduces postoperative anxiety scores and consumption of ropivacaine with fentanyl, decreases side-effects, and improves patient satisfaction.
Detailed Description
The subjects are randomized to the Gabapentin or Placebo group. All patients receive preoperative gabapentin (15 mg/kg, treatment) or placebo, respectively and after surgery either gabapentin (7,5 mg/kg, treatment) or placebo 2 times per day for 3 days, respectively. Patients are subjected to the same anaesthesia protocol. Postoperative analgesia are achieved with either continuous ropivacaine 0.2%/fentanyl 5.0 μg/ml infusion through a thoracic epidural catheter (N=40; Gabapentin n=20, Placebo n=20), or intravenous infusion of morphine (N=40; Gabapentin n=20, Placebo n=20). All patients receive acetaminophen and non-steroidal anti-inflammatory drugs, and metamizol as a "rescue drug" The intravenous infusion of morphine grup was expanded on the basis of the bioethics commission's decision KB-125/2019 (N=64; Gabapentin n=32, Placebo n=32).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Surgery, Thoracic
Keywords
Postoperative pain, Anxiety, Postoperative Complications, Patient Satisfaction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
104 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Gabapentin
Arm Type
Experimental
Arm Description
Single dose preoperative gabapentin. After surgery gabapentin 2 times per day for 3 days.
Arm Title
Placebo Control
Arm Type
Placebo Comparator
Arm Description
Single dose preoperative placebo control. After surgery placebo 2 times per day for 3 days.
Intervention Type
Drug
Intervention Name(s)
Gabapentin
Other Intervention Name(s)
Gabapentin TEVA, capsules
Intervention Description
Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin. Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Patients in this arm of the study receive identical placebo capsules 1 hour before surgery. Patients after surgery receive identical placebo capsules 2 times per day.
Primary Outcome Measure Information:
Title
Pain intensity scores at rest (FLACC for patients <7 y.o., NRS for patients >7 y.o.)
Time Frame
postoperative day: 0-3
Title
Pain intensity scores during deep breathing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)
Time Frame
postoperative day: 0-3
Title
Pain intensity scores during coughing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)
Time Frame
postoperative day: 0-3
Secondary Outcome Measure Information:
Title
Total ropivacaine/fentanyl consumption.
Time Frame
postoperative day: 0-3
Title
Total morphine consumption.
Time Frame
postoperative day: 0-3
Title
Anxiety intensity scores.
Description
Patients rate their anxiety using State-Trait Anxiety Inventory.
Time Frame
before surgery, postoperative day 3
Title
Side Effect Occurrence
Description
Incidence and severity of nausea, vomiting, pruritis, sedation, dizziness, urinary retention, complication in relation to administering of the drugs to epidural space.
Time Frame
first 3 days after surgery
Title
The number of doses of metamizol as a "rescue drug"
Time Frame
postoperative day: 0-3
Title
Patient satisfaction.
Description
Responses can range from 0 (very dissatisfied) to 10 (very satisfied).
Time Frame
first 3 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 5 - 18 years of age; surgery: lateral thoracotomy or Ravitch procedure; ASA 1-3; postoperative analgesia: thoracic epidural analgesia or intravenous infusion of morphine. Exclusion Criteria: allergy or sensitivity to gabapentin; history of chronic pain or daily analgesic use; diagnosed with psychiatric disorders; treated oncologically; with impaired verbal communication; the lack of postoperative chest drainage.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lucyna Tomaszek, PhD
Organizational Affiliation
National Institute for Tuberculosis and Lung Diseases, Poland
Official's Role
Study Director
Facility Information:
Facility Name
Institute for Tuberculosis and Lung Diseases, Pediatric Division
City
Rabka-Zdrój
State/Province
Małopolska
ZIP/Postal Code
34-700
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
20418301
Citation
Rusy LM, Hainsworth KR, Nelson TJ, Czarnecki ML, Tassone JC, Thometz JG, Lyon RM, Berens RJ, Weisman SJ. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010 May 1;110(5):1393-8. doi: 10.1213/ANE.0b013e3181d41dc2.
Results Reference
background
PubMed Identifier
25230144
Citation
Mayell A, Srinivasan I, Campbell F, Peliowski A. Analgesic effects of gabapentin after scoliosis surgery in children: a randomized controlled trial. Paediatr Anaesth. 2014 Dec;24(12):1239-44. doi: 10.1111/pan.12524. Epub 2014 Sep 17.
Results Reference
background
PubMed Identifier
31596461
Citation
Tomaszek L, Fenikowski D, Maciejewski P, Komotajtys H, Gawron D. Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial. Pain Med. 2020 Aug 1;21(8):1562-1571. doi: 10.1093/pm/pnz207.
Results Reference
background

Learn more about this trial

Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin

We'll reach out to this number within 24 hrs